Axsome Secures Exclusive Global Rights to AZD7325 Through New Agreement

Written by Emily J. Thompson, Senior Investment Analyst

ATXI%

AZN+0.43%

AXSM+1.8%

Updated: Nov 06 2025

0mins

Acquisition of AZD7325: Axsome Therapeutics has secured exclusive global rights to AZD7325, a novel oral GABAA receptor modulator, from AstraZeneca, through the acquisition of Baergic Bio, Inc.
Clinical Development Plans: AZD7325, which has shown anti-convulsant effects and a favorable safety profile in over 700 patients, will be evaluated for epilepsy treatment, with Phase 2 trial preparations set to begin in 2026.
Financial Terms of the Agreement: Baergic Bio shareholders will receive an upfront payment of $0.3 million, with potential milestone payments totaling up to $79 million, alongside royalties on global net sales.
AstraZeneca's Compensation: AstraZeneca will receive an upfront cash payment in the single-digit millions and is eligible for various milestone payments and royalties based on the drug's performance.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Axsome Secures Exclusive Global Rights to AZD7325 Through New Agreement

About the author

Top News

Oil Firms Cautious on Venezuela Investment Push

GM Reports $7.1 Billion Charge Amid EV Shift

Stock Market Wraps 2025 with Double-Digit Gains

Novo Nordisk's Weight-Loss Pill Approval: Key Impacts

Related Articles

Realty Income (O): Reliable Dividend Stock with 5.4% Yield

Nvidia (NVDA) Launches Vera Rubin Chip Production Six Months Early, Forecasts 155% Sales Growth

Sigh Up to Get Intellectia Insights

How did the company's recent strategic decisions impact its latest financial performance?

Can you explain the factors behind the recent changes in the company's stock price?

What are the expected impacts of current market trends on the company's future growth?

Based on the latest earnings report, what are the company's forecasted revenues for the next quarter?

How does the company's performance compare to its main competitors in the same sector?

People Also Watch